BioSpace News Archive

The FDA’s Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that tofersen’s effect on neurofilament light chain (NfL) could be a reasonable predictor of clinical benefit.

Sanofi and Regeneron’s Dupixent (dupilumab) met its primary and all secondary endpoints in the Phase III BOREAS trial, significantly reducing severe exacerbations in COPD.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (“Kiora” or the “Company”) today is providing a business update and reporting financial results for the year ended December 31, 2022.

Wednesday, the FDA approved Cidara Therapeutics and Melinta Therapeutics’ Rezzayo (rezafungin) injection to treat candidemia and invasive candidiasis.

Novo Nordisk and Dewpoint Therapeutics have inked a deal to use the latter’s biomolecular condensates discovery platform to treat insulin resistance and diabetic complications.

Ageism, or discrimination against an individual based on their age, is a common barrier many older individuals face in the workplace. Fortunately, there are steps that can be taken to mitigate this discrimination.

Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

Innate Pharma SA reported its consolidated financial results1 for the year ending December 31, 2022.

Basilea Pharmaceutica Ltd announced that its license partner Asahi Kasei Pharma has reported the achievement of a milestone related to the launch of Cresemba® in Japan, which triggered a CHF 5 million payment from AKP to Basilea.

POXEL SA announced that is has finalized agreements with its lenders to restructure its existing debt obligations and a new equity-linked financing with IRIS with an initial drawdown of EUR 3.5 million.